Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Full Abdominoplasty

NCT06545097 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.

NCT NCT06545097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06545097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Full Abdominoplasty
Lead sponsor
Tris Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 3, 2024
Completion date
December 30, 2024
Enrollment
279 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute pain